PepGen Faces FDA Partial Hold on FREEDOM2 DM1 Trial, Advances in Multiple Countries

PepGen announces FDA partial clinical hold on FREEDOM2-DM1 trial due to preclinical questions, while gaining clearance in South Korea, Australia, New Zealand.